Background: Levels of von Willebrand factor antigen (vWF-Ag) increase during combination antiviral therapy of chronic hepatitis C (CHC). The present study investigates the association between these changes in vWF-Ag levels and response to treatment. Methods: Changes in levels of vWF-Ag on antiviral combination treatment in 184 patients with CHC genotype 1 or 4 infections were measured prospectively and effect on response was studied. Results: High on-treatment levels of vWF-Ag were associated with relapse (P<0.01) and low on-treatment levels with sustained virological response (SVR). Receiver operating characteristic curve analysis showed that vWF-Ag levels of <300% at week 12 of therapy have a positive predictive value (PPV) of 78% for SVR.
The standard treatment for chronic hepatitis C (CHC) genotype (GT) 1 and 4 infections with pegylated interferon-α (PEG-IFN-α) and ribavirin [1, 2] is expensive and has potentially severe side effects [3] ; therefore, the tailoring of treatment length is desirable to prevent over-or under-treatment in the individual patient. The best currently available tool for individualization of treatment is sequential determination of viral load on antiviral therapy. Depending on the time to virus undetectability, one can distinguish different response patterns: rapid virological response (RVR; HCV RNA undetectable after 4 weeks), complete early virological response (cEVR; HCV RNA undetectable after 12 weeks), partial EVR (pEVR; <2 log 10 decrease in viral load after 12 weeks) and non-response. These response patterns are used to predict overall treatment outcome [4] .
Patients without EVR are very unlikely to achieve a sustained virological response (SVR; negative predictive value [NPV] of 97-100%) [5, 6] . Approximately 65% [5, 7] of patients with an EVR reach an SVR; however, the positive predictive value (PPV) of EVR on SVR is only 58-72% [5, 6] . Therefore, the identification of further prognostic factors in early virological responders is needed to make tailoring of individual treatment length in these patients possible. This requires a differentiation between patients who will relapse and those who will experience an SVR.
von Willebrand factor (vWF) is a large glycoprotein (GP) with crucial functions in primary haemostasis and coagulation [8] . Interaction of vWF antigen (vWF-Ag) with the platelet receptor GP Ib/V/IX and GPIIb/IIIa leads to platelet adhesion, activation and subsequent platelet-plug formation [9] . vWF-Ag is a known inflammatory marker [10, 11] and mediators of inflammation, such as interleukin (IL)-8 and tumour necrosis factor-α, promote release of vWF-Ag [12] . vWF-Ag circulates in 
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plasma in a tight non-covalently linked complex with coagulation factor VIII (FVIII). vWF-Ag stabilizes FVIII and protects it from degradation; accordingly, FVIII plasma levels are reduced in patients with a severe lack of vWF-Ag [13] .
vWF-Ag levels are markedly increased during combination antiviral therapy of CHC [14, 15] . A 31% increase in vWF-Ag was observed as early as 24 h after administration of a single shot of IFN-α2a. The most pronounced increase in vWF-Ag levels takes place between weeks 0 and 4 of combination antiviral therapy, and the increase is larger in non-cirrhotic patients than in cirrhotic patients.
Haemophilia A patients, who have low FVIII levels, respond better to antiviral therapy than non-haemophiliac patients [16] , and levels of vWF-Ag and FVIII are closely related. We therefore investigated whether there is an association of vWF-Ag levels and response to antiviral therapy. The rationale is that a stronger vWF-Ag response to PEG-IFN-α could be a surrogate marker for a less effective antiviral response in a given patient. Furthermore, the prognostic potential of vWF-Ag on SVR and relapse is examined, and its use in tailoring the length of antiviral treatment for the individual patient is assessed.
Methods

Patients
Individual data from 184 treatment-naive patients who were enrolled in two prospective trials [17, 18] were analysed. Patients with CHC GT 1 or 4 infections were eligible for participation. Standard inclusion and exclusion criteria were applied in these trials. The sample consisted of 62 female and 122 male patients, and the mean ±sd age was 44 ±9.4 years. Liver biopsies were required from all patients and the histological stage of fibrosis was scored according to the Batts and Ludwig scoring system [19] .
Written informed consent was obtained from each patient. The studies were approved by the local ethics committee (Meduniwien, Vienna, Austria) in accordance with the Declaration of Helsinki. All patients were treated with subcutaneous PEG-IFN-α-2a (Pegasys ® ; Roche, Basel, Switzerland) 180 µg/week and oral ribavirin (Copegus ® ; Roche; 200 mg) for 24-72 weeks. A total of 45 (24%) patients were treated for 24 weeks, 93 (51%) for 48 weeks and 46 (25%) were treated for 72 weeks. Ribavirin was dosed according to body weight (<75 kg at 1,000 mg and ≥75 kg at 1,200 mg). In one of the trials, amantadine (200 mg/day) was added to the standard therapy in one study arm, whereas the other received placebo [17] . Data from 21 patients in the amantadine arm and 25 patients from the placebo arm of this study were used. vWF-Ag levels did not differ significantly between patients receiving amantadine and those in the placebo arm of the study at any of the investigated time points (P>0.1). Furthermore, response rates were not significantly different in the amantadine and the placebo groups [17] .
Measurement of HCV, von Willebrand factor antigen levels and factor VIII levels Serum HCV RNA levels were assessed before initiation of treatment and at weeks 4, 8, 12, 24, 48 and 72 during treatment and at follow-up (24 weeks after termination of therapy) by quantitative PCR (limit of quantitation was 50 IU/ml; COBAS ® Amplicor HCV Monitor Test, version 2.0; Roche Diagnostics, Branchburg, NJ, USA). Levels of vWF-Ag were determined in frozen serum samples kept at -70°C by a fully automated STA analyser using vWF-Liatest (Diagnostica Stago, Paris, France) at weeks 4, 8, 12, 24 and follow-up. FVIII levels were determined using the automated one-stage factor VIII:C assay, based on the activated partial thromboplastin time, using actin FS activated partial thromboplastin time reagent (Dade Behring Diagnostics, Marburg, Germany) and FVIII deficient plasma (Technoclone, Vienna, Austria).
Definitions of response
Non-response was defined as the absence of virus negativity throughout 24 weeks of antiviral treatment. SVR was defined as undetectable serum HCV RNA after the follow-up period of 24 weeks. Relapse was defined as undetectable serum HCV RNA at the end of therapy and positive HCV RNA at 24 weeks followup. RVR was defined as undetectable HCV RNA after 4 weeks of therapy. EVR was defined as undetectable HCV RNA (<50 IU/ml by qualitative PCR assay; COBAS ® Amplicor HCV Test, version 2.0; Roche Diagnostics) or >2 log 10 decrease (by the quantitative PCR assay) in HCV RNA levels at week 12 of therapy as compared with baseline [20] . Undetectability of HCV RNA at week 12 is termed a cEVR, whereas a >2 log 10 decrease is termed a pEVR.
Measurement of blood counts and platelet-plug formation
The function of platelet-plug formation was determined by PFA-100. This system measures time taken for a platelet-plug to occlude an aperture in a membrane coated with collagen and epinephrine (CEPI). This time is termed closure time (CT). All other haematological parameters were measured by standard laboratory methods.
Statistical analyses
Statistical analyses were performed using Statistica for Windows version 6.0 (StatSoft, Hamburg, Germany).
Descriptive statistics are provided as mean ± standard deviation. Differences in metric variables among the three response groups were assessed using the KruskalWallis test. Subsequently, differences in metric variables between two response groups were compared by the Mann-Whitney U test. The derived P-values were adjusted using the Bonferroni-Holm correction for multiple testing. Frequencies between groups were compared by the χ 2 test. Correlations between factors were explored by Pearson's correlation analysis. For comparison of slopes, the gradient was first calculated. Further comparisons were carried out by the KruskalWallis and Mann-Whitney U tests. Independence of predictive factors was assessed by multivariate logistic regression. Receiver operating characteristic (ROC) curve analysis was carried out to assess the predictive value of vWF-Ag. PPV was defined as the probability of relapse and NPV was defined as the probability of no relapse occurring. All P-values reported are twosided and P-values <0.05 are considered significant.
Results
A total of 28 out of 184 patients (15%) were nonresponders, 42 (23%) patients relapsed and SVR was achieved in 114 (62%) patients. Baseline characteristics of the relapse group, sustained virological responders and non-responders are given in Table 1 .
Characteristics of the non-response group compared with the sustained virological response group
Patients in the SVR group were significantly younger than non-responders (P=0.023) and had a significantly lower baseline viral load (P=0.024). The CEPI-CT of non-responders was significantly shorter than that of sustained virological responders (P=0.007; Table 1 ). This difference did not persist during therapy.
The mean vWF-Ag levels in the three response groups at weeks 0, 2, 4, 8, 12, 16, 20 and 24 of antiviral therapy, as well as at follow-up, are shown in Figure 1 . Non-responders had higher baseline mean ±sd vWF-Ag levels (217 ±104%) than both relapse and SVR patients (195 ±107% and 171 ±61%, respectively). The baseline difference in vWF-Ag between SVR patients and non-responders did not reach statistical significance (P=0.07; Table 1 ). The same applied to the baseline difference in vWF-levels between relapse and SVR patients (P=0.209) and relapse and non-responder patients (P=0.39; Table 1 ).
During the first 4 weeks of therapy, vWF-Ag levels increased substantially in all three response groups.
Comparison by the Kruskall-Wallis test showed a significant difference in change in vWF-Ag levels (∆vWF-Ag) between the three groups during this time-span (P=0.0012). Further evaluation of the differences between the separate groups revealed that the significant differences in ∆vWF-Ag lay between non-responders and relapsers (P=0.000333) and SVR patients and non-responders (P=0.00221) Evaluation by the Kruskal-Wallis test showed significant differences in vWF-Ag levels between the three response groups starting at week 8 of therapy and continuing to follow-up (P<0.05 at weeks 8, 12 and follow-up, P<0.01 at weeks 16 and 20, and P<0.001 at week 24; Figure 1 ). During antiviral therapy, the mean vWF-Ag level was consistently higher in SVR patients than in non-responders from week 12 onwards, but the difference did not reach statistical significance. Equally, the difference in vWF-Ag levels between the non-response and the relapse group was not significant at any of the investigated time points.
Blood counts and platelet-plug formation
Because vWF-Ag is an important factor in haemostasis, we were interested in whether other parameters that are relevant to haemostasis also differ significantly with respect to response group. Haemoglobin levels, leukocyte count, thrombocyte count and CEPI-CT did not differ significantly between sustained virological responders and relapsers at baseline (Table 1) , or at any of the investigated weeks of therapy. With the exception of CEPI-CT at baseline, the same applied to the difference between these parameters in the nonresponse and relapse groups.
Characteristics of the relapse group compared with the sustained virological response group
In our sample, relapse and SVR groups did not differ significantly in two of the known baseline predictive factors, gender and age. Also, baseline viral load was not significantly different in sustained virological responders and relapsers ( Table 1) . As expected, the frequency of SVR was significantly higher in the RVR group, than in the EVR group and univariate analysis showed a significant association of RVR with SVR (odds ratio 3.325, 95% confidence interval [CI] 1.2-9.1; P=0.02).
vWF antigen levels and response to antiviral therapy
The utility of vWF-Ag levels in distinguishing SVR from relapse patients was examined. Non-response patients were not included in the analysis as they can easily be distinguished from the other two response groups by viral load alone (absence of a <2 log 10 decrease at week 12 of therapy and absence of virus negativity at week 24).
vWF-Ag levels increased during antiviral therapy in both response groups (Figure 1 ). The levels of vWF-Ag were significantly higher in relapsers than in SVR patients from week 8 through to week 24 of therapy (P<0.01 at week 12 and P<0.001 at week 24) . No overlap between the mean values of vWF-Ag ±95% CI in SVR patients and relapsers was observed from week 12 onwards. vWF-Ag levels peaked between weeks 8 and 16 (mean ±95% CI for SVR was 265 ±62% at week 8 and for relapse was 311 ±109% at week 16).
Also, at follow-up, the mean vWF-Ag levels were lower if SVR was reached than if relapse occurred (133% in the SVR group versus 174% in relapse group; P=0.01). Viral load and vWF-Ag were not significantly correlated at any of the investigated time points and multivariable logistic regression analysis showed that vWF-Ag was independent of RVR as a predictor of response.
Determination and performance of cutoff values
Cutoff values for distinguishing relapse patients from SVR patients were determined by ROC curve analysis. Those non-responders (n=8) who reached an EVR and were therefore not distinguishable from sustained virological responders and relapsers by viral load at week 12 were also included in the analysis.
A summary of the predictive vWF-Ag cutoff values obtained for weeks 12 and 24 of therapy, including sensitivities and specificities is given in Table 2 . At week 12, the cutoff value with the maximum accuracy was >296%. For practical purposes, the value of ≥300% was chosen as a simpler cutoff value. The NPV of vWF-Ag values <300% for relapse was 78%. A combined parameter calculated from virus detectability and level of vWF-Ag at week 12 produced an area under the ROC curve (AUC) of 0.769, which is larger than that of vWF-Ag alone (AUC 0.655). Both parameters were independent predictors of response. A cutoff value of <0.4 for the combined parameter corresponds to a NPV of 83.6% for relapse (PPV=70.4%). Figure 2 shows the ROC curve for vWF-Ag at week 12 alone, as well as the ROC curve of the combined parameter.
The predictive potential of vWF-Ag levels increased with the duration of antiviral therapy. Consequently, the maximum AUC was reached at week 24 (0.660). At this point, vWF-Ag levels of <243% had an NPV of 83% for relapse.
Factor VIII levels and response to antiviral therapy As vWF-Ag and FVIII are closely interrelated, we were interested in whether FVIII shows dynamics similar to vWF-Ag during antiviral therapy. Comparing FVIII in the SVR and the relapse groups showed that, similar to vWF-Ag, levels of FVIII increase more in relapsers than in sustained virological responders. This difference is significant (P<0.05), although less so than in vWF-Ag. The mean FVIII levels in the three response groups at weeks 0, 2, 4, 8, 12, 16, 20 and 24 of antiviral therapy as well as at follow-up, are shown in Additional file 1. Correlation between vWF-Ag levels and FVIII levels was strong at all investigated time points (Pearson's correlation coefficient 0.4-0.6; P≤0.0000001).
Fibrosis stage and vWF antigen levels
We investigated whether vWF-Ag levels differ with stage of fibrosis, scored according to the Batts and Ludwig scoring system [19] (F1-F4; F1 n=11, F2 n=102,  F3 n=15 and F4 n=28) . Figure 3 depicts the levels of vWF-Ag during antiviral therapy for the different stages of fibrosis. Throughout treatment, vWF-Ag levels were higher in patients with F4 (cirrhosis) than in all the other groups and this difference was significant (P<0.01) at all investigated time points. vWF-Ag levels did not differ significantly between the patient groups with fibrosis scores of 1, 2 and 3. Overall, the rate of SVR and relapse was independent of the stage of fibrosis, and did not differ among patients with or without cirrhosis (relapse was 36% in cirrhotic patients and 25% in noncirrhotic patients; P=0.2). Multivariate analysis identified vWF-Ag level as a predictor of response, independent of fibrosis score. Accordingly, there was a significant difference in vWF-Ag levels between the relapse and the SVR group for patients with fibrosis scores of 1-3 (n=128) at all investigated time points; however, in cirrhotic patients the difference in vWF-Ag levels between ). VWF12 is the vWF-Ag level at week 12. V12 is 0 if virus negativity is reached at week 12 and 1 if it is not. sustained virological responders and relapsers was not significant. This result might be because of the small sample size (n=33).
Subgroup analysis of early virological responders
Finally, we carried out a subgroup analysis in patients with an EVR. A comparison of SVR group with relapse group was also made. Those non-responders that reached an EVR and could therefore not be identified by virological testing were also included in the analysis (n=8). The size of the EVR group was 129 patients. In this group, relapse occurred in 38 (30%) cases, whereas 83 patients (64%) experienced an SVR and 8 (6%; all with a pEVR) never became HCV-RNA-negative during subsequent therapy. Therefore, a total of 46 (36%) patients who achieved an EVR did not reach an SVR. vWF-Ag levels were continuously higher in the group that relapsed than in the SVR group. This difference was significant from week 4 onwards and at follow-up (P<0.01). The highest significance was reached at week 24 (P<0.001).
Determination and performance of cutoff levels
A synopsis of predictive vWF-Ag cutoff values in the EVR subset along with their corresponding sensitivities and specificities is given in Table 3 . As was found for the entire sample, the predictive potential of vWF-Ag increases with the duration of therapy in early virological responders. At week 12, the vWF-Ag cutoff value with the maximum accuracy for prediction of relapse is >296%; again, we used the cutoff of ≥300%. At week 12, 37 patients (a substantial part of the EVR group [27%]) were above the cutoff value of 300%. At week 24, this was still the case in 28 (21%) patients. vWF-Ag values of <300% at week 12 had an NPV of 74% for relapse. The corresponding value for EVR alone ranged from 58% to 72%.
In EVR patients who had a level of vWF-Ag ≥300% at week 12 of therapy, the rate of relapse was 45% (10/22) when they were treated for a total of 48 weeks, whereas it was 40% (4/10) when they were treated for 72 weeks (P=0.0009). Patients with a level of vWF-Ag ≥300% at week 24 showed a rate of relapse of 53% (8/15) when treated for 48 weeks and 36% (4/11) when treated for 72 weeks (P=0.0218).
Further analysis of complete early virological responders, defined by complete virus negativity at week 12 (n=118), produced an AUC of 0.688 (P=0.0023) at this time point. Again, those non-responders that reached a cEVR (n=2) were included in the analysis. Figure 4 shows the corresponding ROC curve and in these patients a vWF-Ag level of <300% at week 12 has a PPV of 88% on SVR. [19] is shown. Statistically significant differences in vWF-Ag levels between cirrhotic and non-cirrhotic patients (Ludwig scores 1-3 ROC curve analysis of vWF-Ag levels in complete early virological responders at week 24 produced an AUC of 0.742 (P=0.0001). In these patients, a vWF-Ag level of <243% at week 24 had a PPV of 93% on SVR.
Discussion
The results of this study indicate that on combination antiviral therapy, the magnitude of increase in vWF-Ag levels in CHC GT-1-and 4-infected patients is a new predictor of relapse. vWF-Ag levels were significantly higher in relapsers than in patients with SVR at all the investigated time points during therapy. At week 12, vWF-Ag levels of <300% had a PPV of 78% for SVR ( Table 2) . vWF-Ag levels can be determined in most standard hospital laboratories, which renders it a predictive marker that is readily available at economically justifiable costs. In EVR patients, in whom no other prognostic markers are known, levels of vWF-Ag <300% at week 12 indicated that SVR is very probable (74%). The known baseline predictive factors gender, age and viral load [21, 22] did not allow a differentiation between SVR and relapse patients in our sample. As expected, RVR was significantly associated with SVR, but vWF-Ag remained a predictive marker of response to antiviral therapy independent of RVR.
Although the absence of a <2 log 10 decrease in viral load at week 12 is a well-established indicator of non-response [6] , factors that differentiate virological responders who will eventually relapse and those who will reach an SVR are of particular interest. At present, except for RVR, no reliable predictor of SVR is available [23] . The predictive value of an EVR is low; the probability of relapse is still 28-42% [5, 6] when EVR is reached. Therefore, the most desirable quality in an on-treatment predictor of response is the ability to differentiate between those EVR patients who will reach an SVR and those who will relapse. The analysis of GT-1-and GT-4-infected patients with EVR shows that vWF-Ag could be useful for this purpose. In EVR patients, vWF-Ag levels of <300% at week 12 have an NPV of 74% on relapse and so the probability of an SVR is high. In patients with a complete EVR, a vWF-Ag level of <300% at week 12 has a PPV of 88% on SVR. Achievement of EVR alone only has a PPV of 58-72% [5, 6] ; therefore, in early virological responders, the additional measurement of vWF-Ag allows a more precise prediction of response to therapy than viral kinetics alone. Furthermore, SVR rates were significantly higher in EVR patients that were above or equal to the vWF-Ag cutoff level of ≥300% at weeks 12 and 24 if they were treated for a total of 72 weeks instead of 48 weeks (P=0.0009 and P=0.218, respectively).
The changes in FVIII levels were parallel to those of vWF-Ag. They increased during antiviral therapy and more so in the patients that will relapse than in those who will achieve an SVR. These measurements are in accordance with the observation that haemophilia A patients require less substitution of FVIII during antiviral therapy [24] . Haemophiliac patients also show a better response to combination antiviral therapy. This might mean that our findings are not just an epiphenomenon but that there could be a mechanistic explanation for the association of high FVIII levels with relapse and low FVIII levels with SVR [16] .
The question of why the mean levels of vWF-Ag were larger in relapsers than in patients who attained an SVR and in non-responders, remains to be addressed. Treatment with PEG-IFN-α induces systemic inflammation [25] . As vWF-Ag is a known inflammatory marker, the increase in vWF-Ag levels could be attributed to systemic inflammation. This can be interpreted in two ways. Firstly, it could mean that more pronounced inflammation during antiviral therapy is associated with less efficient clearing of virus. There is some evidence to support the suggestion that increased inflammatory activity might inhibit the antiviral effects of PEG-IFN-α. The proinflammatory cytokine IL-8 has been shown to inhibit the antiviral effects of IFN-α in vitro. Proinflammatory cytokines such as tumour necrosis factor-α and IL-8 also promote release of vWF-Ag. Whether vWF-Ag itself might have inhibitory effects on IFN is not clear. Secondly, a less pronounced inflammatory response in sustained virological responders might be because of a faster and more efficient clearing of the virus in these patients. The observation that the rise in vWF-Ag is higher in relapsers than in non-responders remains puzzling. The fact that non-responders start at a higher pretreatment level of vWF-Ag might contribute to this observation: these patients might have less reserves for generating an inflammatory response.
We conclude that vWF-Ag is a useful additional factor in the prediction of response to combination antiviral therapy of CHC. It might also be helpful in tailoring treatment length, especially in those patients that are classified as early virological responders by viral kinetics.
This proposition is supported by significantly higher SVR rates in patients that were above the suggested vWF-Ag level of ≥300% at weeks 12 and 24 and were treated for 72 instead of 48 weeks; however, prospective trials are needed to assess this concept. The exact mechanisms that lead to the higher vWF-Ag levels in those patients that will suffer a relapse remain to be elucidated.
